Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review

Jean L1, Audrey M1, Beauchemin C1, Consortium OBOTI2. Can J Gastroenterol Hepatol. 2018 Jun 13;2018:7439730. doi: 10.1155/2018/7439730. eCollection 2018.

Author information

1 Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada.

2 Montreal Heart Institute, 5000 Bélanger, Room S-6300, Montreal, QC, Canada H1T 1C8.


OBJECTIVE: The objective of this literature review was to evaluate the existing evidence regarding the cost-effectiveness of treatment options in IBD.

METHODS: A systematic review of the literature was conducted to identify economic evaluations of IBD therapy. The literature search was performed using electronic databases MEDLINE and EMBASE. Searches were limited to full economic evaluations published in English or French between 2004 and 2016.

RESULTS: A total of 5,403 potentially relevant studies were identified. After screening titles and abstracts, 48 studies were included, according to the eligibility criteria. A total of 56% and 42% of the studies were assessing treatments of UC or CD, respectively. Treatment options under evaluation included biological agents, mesalamine, immunosuppressants, and surgery. The majority of studies evaluated the cost-effectiveness of biological treatments. Biological therapies were dominant in 23% of the analyses and were cost-effective according to a $CAD50,000/QALY and $CAD100,000/QALY threshold in 41% and 62% of the analyses, respectively.

CONCLUSION: This literature review provided a comprehensive overview of the economic evaluations for the different treatment options for IBD over the past 12 years and represents a helpful reference for future economic evaluations.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.